and were commercially patented and implemented first in
Germany in 1980 [26]. ATAD relies on the solubilisation of suffi-cient oxygen in a reactor so that the resulting high levels of aerobic
bacterial metabolic activity generate a high operating tempera-ture (>60 ◦C), leading to rapid inactivation of viral and mesophilic
bacterial pathogens